Immunotherapy combo trial aims to boost survival in head and neck cancer
NCT ID NCT07362979
First seen Jan 30, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This phase II trial is testing whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiotherapy, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be randomly assigned to one of three treatment combinations. The goal is to find which combination offers the best chance of preventing the cancer from returning or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Guangdong Medical University
RECRUITINGZhanjiang, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen
RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dongguan People's Hospital
RECRUITINGDongguan, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (an immunotherapy drug) combined with platinum-based chemotherapy (gemcitabine, cisplatin, or nab-paclitaxel)
What this could lead to
If successful, this could identify a more effective treatment combination for advanced nasopharyngeal cancer, potentially improving survival rates.
What could go wrong
This is an early phase II trial with a moderate size (243 participants). Results may not confirm benefit, and side effects from combining immunotherapy with chemotherapy can be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.